AbbottABT recently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...

Initial results from more than 800 atrial fibrillation patients presented at Transcatheter Cardiovascular Therapeutics 2016 indicate the AMPLATZER™ Amulet™ LAA Occluder is a safe alternative to ...

ST. PAUL, Minn.--St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its AMPLATZER™ Amulet™ Left Atrial Appendage Occluder. The Amulet device is used ...

Abbott Laboratories (NYSE:ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased risk for air bubbles (air emboli) to be introduced into patients who have procedures with this ...

Please provide your email address to receive an email when new articles are posted on . In patients who have a stroke or transient ischemic attack related to the patent foramen ovale, percutaneous ...

The Amplatzer PFO Occluder from St. Jude Medical has been approved by FDA to close patent foramen ovale in ischemic stroke patients. St. Jude Medical's Amplatzer PFO Occluder for patent foramen ovale ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...